Khat abuse as risk factor for development of psychotic symptoms in trauma patients : a feasibility study for further genetico-epidemiological studies in the GGFRC, ethiopia

dc.contributor.authorAdorjan, Kristina
dc.contributor.authorWidmann, Marina
dc.contributor.authorTesfaye, Markos
dc.contributor.authorTessema, Fasil
dc.contributor.authorToennes, Stefan
dc.contributor.authorSuleman, Sultan
dc.contributor.authorSusser, Ezra
dc.contributor.authorPapiol, Sergi
dc.contributor.authorSoboka, Matiwos
dc.contributor.authorOdenwald, Michael
dc.date.accessioned2018-02-15T17:01:52Z
dc.date.available2018-02-15T17:01:52Z
dc.date.issued2017eng
dc.description.abstractThe Jimma University in southwestern Ethiopia has a unique health and demographic surveillance system called „Gilgel Gibe Field Research Center” (GGFRC) with a catchment area of about 50.000 people. In this setting, we studied the effect of khat use as risk factor for the development and the stability of psychotic symptoms among young men in the community. Our aim was to validate pilot data by testing the hypothesis, whether objective biological data on khat abuse are related in a meaningful way to behavioral self-reports of study participants and psychiatric symptom presentation assessed by trained interviewers. We assumed that khat alkaloids in urine samples of respondents are related to a higher probability of psychotic symptom presentation, especially in the subgroup with high trauma load. Furthermore, we wanted to demonstrate the reliability and validity of research methods that are necessary for future genetic epidemiological studies, i.e. the validity and reliability of pharmacological screening tests as well as assessments performed by trained local interviewers.eng
dc.description.versionpublishedeng
dc.identifier.doi10.1016/j.euroneuro.2016.09.545eng
dc.identifier.urihttps://kops.uni-konstanz.de/handle/123456789/41385
dc.language.isoengeng
dc.subject.ddc150eng
dc.titleKhat abuse as risk factor for development of psychotic symptoms in trauma patients : a feasibility study for further genetico-epidemiological studies in the GGFRC, ethiopiaeng
dc.typeINPROCEEDINGSeng
dspace.entity.typePublication
kops.citation.bibtex
@inproceedings{Adorjan2017abuse-41385,
  year={2017},
  doi={10.1016/j.euroneuro.2016.09.545},
  title={Khat abuse as risk factor for development of psychotic symptoms in trauma patients : a feasibility study for further genetico-epidemiological studies in the GGFRC, ethiopia},
  number={27, Suppl 3},
  issn={0924-977X},
  publisher={Elsevier},
  address={Amsterdam},
  series={European Neuropsychopharmacology},
  booktitle={Abstracts of the XXIV World Congress of Psychiatric Genetics (WCPG)},
  author={Adorjan, Kristina and Widmann, Marina and Tesfaye, Markos and Tessema, Fasil and Toennes, Stefan and Suleman, Sultan and Susser, Ezra and Papiol, Sergi and Soboka, Matiwos and Odenwald, Michael}
}
kops.citation.iso690ADORJAN, Kristina, Marina WIDMANN, Markos TESFAYE, Fasil TESSEMA, Stefan TOENNES, Sultan SULEMAN, Ezra SUSSER, Sergi PAPIOL, Matiwos SOBOKA, Michael ODENWALD, 2017. Khat abuse as risk factor for development of psychotic symptoms in trauma patients : a feasibility study for further genetico-epidemiological studies in the GGFRC, ethiopia. XXIV World Congress of Psychiatric Genetics (WCPG). Jerusalem, Israel, 30. Okt. 2016 - 4. Nov. 2016. In: Abstracts of the XXIV World Congress of Psychiatric Genetics (WCPG). Amsterdam: Elsevier, 2017, pp. S468. European Neuropsychopharmacology. 27, Suppl 3. ISSN 0924-977X. eISSN 1873-7862. Available under: doi: 10.1016/j.euroneuro.2016.09.545deu
kops.citation.iso690ADORJAN, Kristina, Marina WIDMANN, Markos TESFAYE, Fasil TESSEMA, Stefan TOENNES, Sultan SULEMAN, Ezra SUSSER, Sergi PAPIOL, Matiwos SOBOKA, Michael ODENWALD, 2017. Khat abuse as risk factor for development of psychotic symptoms in trauma patients : a feasibility study for further genetico-epidemiological studies in the GGFRC, ethiopia. XXIV World Congress of Psychiatric Genetics (WCPG). Jerusalem, Israel, Oct 30, 2016 - Nov 4, 2016. In: Abstracts of the XXIV World Congress of Psychiatric Genetics (WCPG). Amsterdam: Elsevier, 2017, pp. S468. European Neuropsychopharmacology. 27, Suppl 3. ISSN 0924-977X. eISSN 1873-7862. Available under: doi: 10.1016/j.euroneuro.2016.09.545eng
kops.citation.rdf
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/41385">
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/43"/>
    <dc:contributor>Tesfaye, Markos</dc:contributor>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/41385"/>
    <dc:creator>Odenwald, Michael</dc:creator>
    <dcterms:title>Khat abuse as risk factor for development of psychotic symptoms in trauma patients : a feasibility study for further genetico-epidemiological studies in the GGFRC, ethiopia</dcterms:title>
    <dc:contributor>Tessema, Fasil</dc:contributor>
    <dcterms:abstract xml:lang="eng">The Jimma University in southwestern Ethiopia has a unique health and demographic surveillance system called „Gilgel Gibe Field Research Center” (GGFRC) with a catchment area of about 50.000 people. In this setting, we studied the effect of khat use as risk factor for the development and the stability of psychotic symptoms among young men in the community. Our aim was to validate pilot data by testing the hypothesis, whether objective biological data on khat abuse are related in a meaningful way to behavioral self-reports of study participants and psychiatric symptom presentation assessed by trained interviewers. We assumed that khat alkaloids in urine samples of respondents are related to a higher probability of psychotic symptom presentation, especially in the subgroup with high trauma load. Furthermore, we wanted to demonstrate the reliability and validity of research methods that are necessary for future genetic epidemiological studies, i.e. the validity and reliability of pharmacological screening tests as well as assessments performed by trained local interviewers.</dcterms:abstract>
    <dc:creator>Tessema, Fasil</dc:creator>
    <dc:contributor>Toennes, Stefan</dc:contributor>
    <dc:contributor>Suleman, Sultan</dc:contributor>
    <dc:contributor>Soboka, Matiwos</dc:contributor>
    <dc:creator>Suleman, Sultan</dc:creator>
    <dc:contributor>Adorjan, Kristina</dc:contributor>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2018-02-15T17:01:52Z</dc:date>
    <dc:contributor>Widmann, Marina</dc:contributor>
    <dc:contributor>Susser, Ezra</dc:contributor>
    <dc:language>eng</dc:language>
    <dc:creator>Soboka, Matiwos</dc:creator>
    <dc:creator>Papiol, Sergi</dc:creator>
    <dc:contributor>Odenwald, Michael</dc:contributor>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2018-02-15T17:01:52Z</dcterms:available>
    <dc:contributor>Papiol, Sergi</dc:contributor>
    <dc:creator>Toennes, Stefan</dc:creator>
    <dcterms:issued>2017</dcterms:issued>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/43"/>
    <dc:creator>Adorjan, Kristina</dc:creator>
    <dc:creator>Susser, Ezra</dc:creator>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dc:creator>Widmann, Marina</dc:creator>
    <dc:creator>Tesfaye, Markos</dc:creator>
  </rdf:Description>
</rdf:RDF>
kops.conferencefieldXXIV World Congress of Psychiatric Genetics (WCPG), 30. Okt. 2016 - 4. Nov. 2016, Jerusalem, Israeldeu
kops.date.conferenceEnd2016-11-04eng
kops.date.conferenceStart2016-10-30eng
kops.flag.etalAuthortrueeng
kops.flag.knbibliographytrue
kops.location.conferenceJerusalem, Israeleng
kops.sourcefield<i>Abstracts of the XXIV World Congress of Psychiatric Genetics (WCPG)</i>. Amsterdam: Elsevier, 2017, pp. S468. European Neuropsychopharmacology. 27, Suppl 3. ISSN 0924-977X. eISSN 1873-7862. Available under: doi: 10.1016/j.euroneuro.2016.09.545deu
kops.sourcefield.plainAbstracts of the XXIV World Congress of Psychiatric Genetics (WCPG). Amsterdam: Elsevier, 2017, pp. S468. European Neuropsychopharmacology. 27, Suppl 3. ISSN 0924-977X. eISSN 1873-7862. Available under: doi: 10.1016/j.euroneuro.2016.09.545deu
kops.sourcefield.plainAbstracts of the XXIV World Congress of Psychiatric Genetics (WCPG). Amsterdam: Elsevier, 2017, pp. S468. European Neuropsychopharmacology. 27, Suppl 3. ISSN 0924-977X. eISSN 1873-7862. Available under: doi: 10.1016/j.euroneuro.2016.09.545eng
kops.title.conferenceXXIV World Congress of Psychiatric Genetics (WCPG)eng
relation.isAuthorOfPublication80617bf5-9f16-458b-b244-89040e36e0e7
relation.isAuthorOfPublicatione258db57-c565-40ea-b5b8-4da2506102d7
relation.isAuthorOfPublication.latestForDiscovery80617bf5-9f16-458b-b244-89040e36e0e7
source.bibliographicInfo.fromPageS468eng
source.bibliographicInfo.seriesNumber27, Suppl 3eng
source.identifier.eissn1873-7862eng
source.identifier.issn0924-977Xeng
source.publisherElseviereng
source.publisher.locationAmsterdameng
source.relation.ispartofseriesEuropean Neuropsychopharmacologyeng
source.titleAbstracts of the XXIV World Congress of Psychiatric Genetics (WCPG)eng

Dateien